LSPN Spring North America 2026

The LSPN Spring North America 2026 Conference took place on 29–30 April 2026 at The Hyatt Regency in Boston. The event brought together leading intellectual property experts from the pharmaceutical, biotechnology and medical-technology industries.

This significant event served as a centre for ground-breaking insights, featuring a programme carefully designed to cover every aspect of patent management throughout your product’s life cycle. The conference presented an excellent mix of expert presentations, panel discussions and roundtables aimed at fostering both casual networking and informative exchanges — allowing participants to learn from each other’s experiences.

The conference boasted a substantial turnout, with over half of the attendees being in-house professionals from pharmaceutical, biotech and medtech companies.

Hosted by Life Sciences Intellectual Property Review, this conference has become the leading event for professionals navigating the intricacies of life sciences intellectual property.

Below, you can view videos featuring speakers from organisations such as Gilead Sciences, Novartis, Takeda Pharmaceuticals, Bristol Myers Squibb, Regeneron, The Broad Institute of MIT and Harvard, New England Biolabs, Alnylam Pharmaceuticals, Beam Therapeutics, Editas, Isomorphic Labs, BlueRock Therapeutics, Generate Biomedicines, Kymera Therapeutics, Sumitomo Pharma America, Finnegan, Cooley, McDermott Will & Schulte, Goodwin Law, Akin Gump, Venable, Choate, Carpmaels & Ransford, Wolf Greenfield and Sanofi.

WATCH: AI-powered patent prosecution for life sciences innovation

Integrating AI into patent workflows promises efficiency gains, but requires strict oversight regarding accuracy, ethics, and data security. This panel explores the practical realities of deploying AI tools responsibly while maintaining the high standards required in life sciences prosecution.

WATCH: Life after ADI 5529—how Brazil is redesigning its patent system since 2021, from patent term extensions to patent certainty

30 May 2026

WATCH: Post-grant proceedings in life sciences—strategic offense and defense in the US and Europe

29 May 2026

Asia

WATCH: China patent landscape

The regulatory and IP environment in China is shifting at a rapid pace, bringing new measures, guiding cases, and compliance hurdles. This session provides a high-level overview of the past year’s critical changes and what life sciences companies must anticipate on the horizon.

Unified Patent Court

WATCH: Navigating parallel EPO and UPC revocation actions: strategies, opportunities, and risks

Managing parallel revocation actions requires a meticulous approach to forum choice and sequencing. This presentation unpacks the lessons learned from the first year of simultaneous EPO and UPC proceedings, offering tactics to leverage opportunities and minimise cross-border risks.

Americas

WATCH: Overcoming patent eligibility, patentability, and disclosure requirements in life sciences innovation

How can innovators secure reliable protection across diagnostics, genetics, and AI-integrated devices while navigating Section 101 and 112 pitfalls? This comprehensive panel addresses strategies to clear fundamental patentability hurdles amid shifting court decisions and USPTO guidelines.

Americas

WATCH: Gene editing and advanced therapies—patent strategies for the next generation of precision medicine

The rapid evolution of CRISPR and base editing brings transformative medical potential alongside deeply complex IP and licensing hurdles. This session explores how companies can balance innovation with risk mitigation in a crowded and highly contested precision medicine landscape.

Americas

WATCH: Defending market exclusivity through Hatch-Waxman and BPCIA litigation strategies

The influx of biosimilars and generics requires innovator companies and challengers alike to continually refine their litigation tactics. This panel dissects current trends in Hatch-Waxman and BPCIA frameworks, providing a roadmap for defending franchises and navigating market entry.

Americas

WATCH: Positioning for success—preparing for and managing patent disputes under Hatch-Waxman and the BPCIA

Success in complex pharmaceutical litigation often comes down to early preparation and cross-functional alignment. This session explores how companies can proactively manage Hatch-Waxman and BPCIA disputes through strategic front-end planning and operational execution.

Europe

WATCH: Assessing inventive step in Europe—diverging standards at the EPO and the UPC?

Are the EPO and the UPC diverging in their assessment of inventive step? By analysing key recent pharmaceutical decisions, this presentation highlights potential differences in standards and considers how they impact European patent strategies.

Americas

WATCH: Navigating the regulatory-IP nexus—maximizing exclusivity in an evolving policy landscape

The intersection of regulatory strategy and intellectual property protection has become critical to maintaining market exclusivity. This panel examines how life sciences companies can adapt their IP strategies in response to shifting FDA guidance, biosimilar challenges, and evolving agency priorities.

WATCH: Overcoming obstacles in antibody patent protection

16 May 2026 As antibodies cement their status as a major therapeutic class, securing robust IP protection has grown increasingly difficult. With heightened scrutiny on enablement and written description requirements, this panel unpacks strategies for building resilient antibody portfolios in a challenging global landscape.

WATCH: Facilitating access to the UPC—economics and navigating the UPC-US patent nexus

15 May 2026 Understanding the economic mechanisms and cross-border interactions of the UPC is crucial for modern patent litigation. This session untangles the complexities of evidence gathering and cost security, highlighting the critical interplay between European proceedings and US patent strategies.

WATCH: Latest developments from the UPC

14 May 2026 Are life sciences cases gaining momentum in the new Unified Patent Court? This session provides a critical update on the UPC's evolving jurisprudence, looking at emerging legal tests and the specific challenges of preliminary injunctions for life sciences products.

LSPN Spring North America 2026

Get up-to-date information on all our publications and events